TrialArthritis research & therapy2024

A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.

Stanley Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.